Is AbbVie Stock Underperforming the Dow?

Core Insights - AbbVie Inc. is a biopharmaceutical company with a market cap of $397.3 billion, focusing on immunology, oncology, neuroscience, eye care, and aesthetics [1] - AbbVie is classified as a "mega-cap stock" due to its market cap exceeding $200 billion, highlighting its size and influence in the drug manufacturing industry [2] Financial Performance - AbbVie shares have declined 6.3% from their 52-week high of $244.81, reached on October 1, 2025, and have fallen 2.9% over the past three months, underperforming the Dow Jones Industrial Average's 5.5% increase [3] - Year-to-date, AbbVie shares are up marginally, while the Dow Jones Industrial Average has returned 1.5%. Over the past 52 weeks, AbbVie has increased by 13.6%, outperforming the Dow Jones Industrial Average's 12.4% rise [5] - In Q4, AbbVie's net revenue rose 10% year-over-year to $16.6 billion, exceeding consensus estimates by 1.6%. The adjusted EPS of $2.71 grew 25.5% from the previous year, surpassing analyst expectations of $2.66 [7] Market Position and Analyst Sentiment - AbbVie has outperformed Pfizer Inc.'s 1.7% increase over the past 52 weeks but has lagged behind Pfizer's 8.8% year-to-date growth [8] - Analysts maintain a moderately optimistic outlook for AbbVie, with a consensus rating of "Moderate Buy" from 30 analysts and a mean price target of $248.44, indicating an 8.3% premium to current price levels [8]